MeritValue

Kraig Biocraft Laboratories, Inc.

KBLBdata completeness 75%19 fiscal years on file

Data notes: no data for concept 'investmentsAtFairValue'; no data for concept 'netInvestmentIncome'; no data for concept 'gainsOnRealEstateSales'; no data for concept 'realEstateImpairment'; no data for concept 'dividendsPaid'

i. The business — what you’d actually own
FigureFY 2021FY 2022FY 2023FY 2024FY 2025
Revenue—————
Net income−$8.05M1−$3.84M2−$3.03M3−$3.4M4−$3.62M4
Operating cash flow−$1.8M5−$1.89M6−$1.24M7−$1.84M8−$1.79M8
Capital expenditure$97,1549$5,02110$6,39911$4,24012$5,39512
Free cash flow (derived)−$1.9M5−$1.89M6−$1.25M7−$1.84M8−$1.79M8
Total debt—————
Cash & equivalents—$3.86M13$2.55M14$673,26415$1.79M15
Diluted shares877.6M974.3M1.03B1.04B1.06B

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal
If you owned
shares
Net assets behind them
−$0.08
your share of equity
Profit it earned you last year
−$0.03
Free cash flow it threw off
−$0.02
Debt you’d be carrying
—

10 shares is a claim on −$0.08 of net worth that earned you −$0.03 and generated −$0.02 of cash last year.

iii. Is this a good business?
Moat signal · return on equity
— avg · 5y

Not enough data in the filings for a return-on-capital reading.

seeing a moat in the numbers →
Management signal · capital allocation
+21% shares · 5y

Share count is up 21% over 5 years — owners have been diluted. Worth asking what they got for it.

reading capital allocation →

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.5.0
DCF · Growth Exit 10Y
not applicable
3y-median FCF non-positive — growth-exit DCF not applicable (see EPV)
DCF · Growth Exit 5Y
not applicable
3y-median FCF non-positive — growth-exit DCF not applicable (see EPV)
Earnings Power Value
not applicable
normalized (5y-median) earnings non-positive — EPV undefined
Graham Number
not applicable
diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts
  1. 10-K · period ending 2021-12-31 · accession 0001493152-23-009476 (NetIncomeLoss)
  2. 10-K · period ending 2022-12-31 · accession 0001493152-24-012404 (NetIncomeLoss)
  3. 10-K · period ending 2023-12-31 · accession 0001641172-25-001238 (NetIncomeLoss)
  4. 10-K · period ending 2024-12-31 · accession 0001493152-26-013630 (NetIncomeLoss)
  5. 10-K · period ending 2021-12-31 · accession 0001493152-23-009476 (NetCashProvidedByUsedInOperatingActivities)
  6. 10-K · period ending 2022-12-31 · accession 0001493152-24-012404 (NetCashProvidedByUsedInOperatingActivities)
  7. 10-K · period ending 2023-12-31 · accession 0001641172-25-001238 (NetCashProvidedByUsedInOperatingActivities)
  8. 10-K · period ending 2024-12-31 · accession 0001493152-26-013630 (NetCashProvidedByUsedInOperatingActivities)
  9. 10-K · period ending 2021-12-31 · accession 0001493152-23-009476 (PaymentsToAcquirePropertyPlantAndEquipment)
  10. 10-K · period ending 2022-12-31 · accession 0001493152-24-012404 (PaymentsToAcquirePropertyPlantAndEquipment)
  11. 10-K · period ending 2023-12-31 · accession 0001641172-25-001238 (PaymentsToAcquirePropertyPlantAndEquipment)
  12. 10-K · period ending 2024-12-31 · accession 0001493152-26-013630 (PaymentsToAcquirePropertyPlantAndEquipment)
  13. 10-K · period ending 2022-12-31 · accession 0001493152-24-012404 (CashAndCashEquivalentsAtCarryingValue)
  14. 10-K · period ending 2023-12-31 · accession 0001641172-25-001238 (CashAndCashEquivalentsAtCarryingValue)
  15. 10-K · period ending 2024-12-31 · accession 0001493152-26-013630 (CashAndCashEquivalentsAtCarryingValue)